Identification, preparation, and characterization of several polymorphs and solvates of terazosin hydrochloride

Journal of Pharmaceutical Sciences

Volumn 95, Issue 4, 2006, Pages 917-928

  Bauer, J ^a   Morley, J ^a   Spanton, S ^a   Leusen, F J J ^b   Henry, R ^a   Hollis, S ^a   Heitmann, W ^a   Mannino, A ^a   Quick, J ^a   Dziki, W ^a  

^a ABBOTT LABORATORIES   (United States)

^b Accelrys Limited UK   (United Kingdom)

Author keywords

Dehydrate; Methanolate; Molecular modeling; Polymorphs; Terazosin; X ray diffraction

Indexed keywords

TERAZOSIN;

ARTICLE; CRYSTAL STRUCTURE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG IDENTIFICATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; GRAVIMETRY; INFRARED SPECTROSCOPY; MICROSCOPY; MOLECULAR MODEL; NUCLEAR MAGNETIC RESONANCE; ROOM TEMPERATURE; SOLID STATE; SOLUBILITY; SOLVATION; THERMAL ANALYSIS; X RAY DIFFRACTION;

EID: 33645999665     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20425     Document Type: Article

References (35)

1. Tsuchihashi H, Nagatomo T. 1989. Alpha-blocking potencies of antihypertensive agents (prazosin, teraazosin, bunazosin, SGB-1534 and ketanserin) with quinazoline or quinazolinedione as assassed by radioligand binding assay methods in rat brain. J Pharmacobio Dyn 12:170-174.
2. Nagatomo T, Tajiri A, Nakamura T, Hokibara R, Tanaka Y, Aono J, Tsuchihasi H. 1987. Chem Pharm Bull 35:1629-1632.
3. Chrysant S, Bal I, Johnson B, McPherson M. 1985. Anti-hypertensive effectiveness of terazosin: A new long acting alpha adrenergic inhibitor. Clin Cardiol 8:486-489.
4. Graham R. 1984. Am J Cardiol 53:16A-20A.
5. Nelson E, Pool J, Taylor A, Mitchell J. 1982. Clin Pharmacol Ther (St. Louis) 31:255.
6. Abraham P, Halstenson C, Matzke G, Napier J, Keane W. 1985. Pharmacotherapy (Carlisle, Mass) 5:285-289.
7. Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G. 1996. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 335:533-539.
8. Roehrborn CG, Oesterling JE, Auerbach S, Kaplan SA, Lloyd LK, Milam DF, Padley RJ. 1996. The Hytrin Community Assessment Trial Study: A one year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. Urology 47:159-168.
9. Bernstein J. 2002. Polymorphism in Molecular Crystals. New York: Oxford University Press.
10. Rodriguez-Sponga B, Price C, Jayasankar A, Matzger A, Rodriguez-Hornedo N. 2004. General principles of pharmaceutical solid polymorphism: A supramolecular perspective. Adv Drug Deliv Rev 56:241-274.
11. Byrn SR, Pfeiffer RR, Stowell JG. 1999. Solid-State Chemistry of Drugs. (2nd ed), West Lafayette, IN: SSCI Inc.
12. Grant DW, Byrn SR. 2004. A timely re-examination of drug polymorphism in pharmaceutical development and regulation, Adv Drug Deliv Rev 56:237-239.
13. Haleblian J, McCrone W. 1969. Pharmaceutical applications of polymorphism. J Pharm Sci 58:911-929.
14. Dunitz J, Bernstein J. 1995. Disappearing polymorphs. J Acc Chem Res 28:193-200.
15. Hassan M, et al. 1997. Characterization of famotidine polymorphs, inter. J Pharmaceutics 149:227-232.
16. Winn M, Kyncl J, et al. 1977. Antihypertensive agents. U.S. Patent 4112097
17. Meyer G, Bauer J. 1994. Terazosin polymorph and pharmaceutical composition. U.S.Patent 5294615.
18. Bauer J, Morley J. 1994. Terazosin polymorph and pharmaceutical composition. U.S. Patent 5362730.
19. Morley J, Bauer J. 1995. Terazosin monohydrochloride and processes and intermediates for its production. U.S. Patent 5412095.
20. Mannino A, Henry R, et al. 1996. process and intermediate for the preparation of terazosin hydrochloride dihydrate. U.S. Patent 5,504,207.
21. Patel M, et al. 1995. Terazosin crystalline polymorph and pharmaceutical compositions thereof. U.S. Patent 5,587,377.
22. Burger A, Ramberger R. 1979. On the polymorphism of pharmaceuticals and other molecular crystals II. Mikrochim Acta (Wien) 11:273-316.
23. Stephenson G, Groleau E, Kleemann R, Xu W, Rigsbee D. 1998. Formation of isomorphic desolvates: Creating a molecular vacuum. J Pharm Sci 87:536-541.
24. Brittain HG. 2002. X-ray powder diffraction of pharmaceutical materials. Am Pharm Rev 5:74-76, 78, 80.
25. Grzesiak AL, Lang M, Kim K, Matzger AJ. 2003. Comparison of the four anhydrous polymorphs of carbamazepine and the crystal structure of form I. J Pharm Sci 92:2260-2271.
26. Gu CH, Grant DJW. 2001. Estimating the relative stability of polymorphs and hydrates from heats of solution and solubility data. J Pharm Sci 90:1277-1287.
27. Malpezzi L, Magnone GA, Masciocchi N, Sironi A. 2005. Single crystal and powder diffraction characterization of three polymorphic forms of acitretin. J Pharm Sci 94:1067-1078.
28. Tishmack PA, Bugay DE, Byrn SR. 2003. Solid-state nuclear magnetic resonance spectroscopy-Pharmaceutical applications. J Pharm Sci 92:441-474.
29. Phadnis NV, et al. 1997. Polymorphism in anhydrous theophylline- Implications on the dissolution rate of theophylline tablets. J Pharm Sci 86:1256-1263.
30. Apperley D, Fletton R, Harris R, Lancaster T, Tavener S, Threlfall T. 1999. Sulfathiazole polymorphism studied by Magic-Angle Spinning NMR. J Pharm Sci 88:1275-1280.
31. Kuhnert-Brandstatter M. 1999. Demonstration of the terms enantiotropy and monotropy in polymorphism research exemplified by flurbiprofen. J Pharm Sci 88:103-108.
32. Leusen FJJ. 1996. Ab initio prediction of polymorphs. J Crystal Growth 166:900-903.
33. Verwer P, Leusen FJJ. 1998. Computer simulation to predict possible crystal polymorphs. Rev Comp Chem 12:327-365.
34. Mayo SL, Olafson BD, Goddard WA, III. 1990. DREIDING: A generic force field for molecular simulations. J Phys Chem 94:8897-8909.
35. Rietveld HM. 1969. A profile refinement method for nuclear and magnetic structures. J Appl Crystallogr 2:65-71.